Announced details
Colorectal cancer screening, CT colon examinations, medical AI
Completed clinical trials in Japan
TOHO HOLDINGS CO.,LTD. made an investment through the CVC fund “TOHO Ventures.” The limited partner of TOHO Ventures is TOHO HOLDINGS CO.,LTD.
Head office: Chuo-ku, Tokyo; Representative: Okamoto Masaki (岡本 将輝); Established: April 2023; Business: Development and clinical deployment of a non-invasive AI colorectal cancer screening system
FDA Breakthrough Device designation, selection for the FDA TAP Program, designation by the Ministry of Health, Labour and Welfare as a product eligible for priority review and other measures for software as a medical device
U.S. Food and Drug Administration (FDA), Ministry of Health, Labour and Welfare
Chuo-ku, Tokyo (Boston Medical Sciences Co., Ltd.)
The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Laxative-Free Virtual Endoscopy® Examination System |
| Counterparty | Boston Medical Sciences Co., Ltd. |
| Counterparty overview | Head office: Chuo-ku, Tokyo; Representative: Okamoto Masaki (岡本 将輝); Established: April 2023; Business: Development and clinical deployment of a non-invasive AI colorectal cancer screening system |
| Relationship with the Company | TOHO HOLDINGS CO.,LTD. made an investment through the CVC fund “TOHO Ventures.” The limited partner of TOHO Ventures is TOHO HOLDINGS CO.,LTD. |
| Applicable area | Colorectal cancer screening, CT colon examinations, medical AI |
| Award/certification name | FDA Breakthrough Device designation, selection for the FDA TAP Program, designation by the Ministry of Health, Labour and Welfare as a product eligible for priority review and other measures for software as a medical device |
| Awarding / certifying body | U.S. Food and Drug Administration (FDA), Ministry of Health, Labour and Welfare |
| Location | Chuo-ku, Tokyo (Boston Medical Sciences Co., Ltd.) |
| Usage history | Completed clinical trials in Japan |
| Impact on Business Performance | The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The investment was based on an assessment of BMS’s AI technology development capabilities, its response to the medical need to reduce the burden of colorectal cancer screening, and progress in development and regulatory activities in Japan and overseas, as well as expectations for business synergies and value creation through the use of TOHO HOLDINGS CO.,LTD.’s pharmaceutical distribution network.